US009114172B2

(12) **United States Patent**
Rhee et al.

(10) **Patent No.: US 9,114,172 B2**
(45) **Date of Patent: Aug. 25, 2015**

(54) **RAPIDLY ACTING DRY SEALANT AND METHODS FOR USE AND MANUFACTURE**

(71) Applicants: **Baxter International Inc.**, Deerfield, IL (US); **Baxter Healthcare S.A.**, Glattpark (Opfikon) (CH)

(72) Inventors: **Woonza M. Rhee**, Palo Alto, CA (US); **Cary J. Reich**, Los Gatos, CA (US); **A. Edward Osawa**, San Francisco, CA (US); **Felix Vega**, San Francisco, CA (US)

(73) Assignees: **Baxter International Inc.**, Deerfield, IL (US); **Baxter Healthcare S.A.**, Glattpark (Opfikon) (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 13 days.

(21) Appl. No.: **13/781,326**

(22) Filed: **Feb. 28, 2013**

(65) **Prior Publication Data**

US 2014/0072614 A1 Mar. 13, 2014

Related U.S. Application Data

(60) Division of application No. 13/457,178, filed on Apr. 26, 2012, now abandoned, which is a continuation of application No. 11/832,380, filed on Aug. 1, 2007.

(60) Provisional application No. 60/821,190, filed on Aug. 2, 2006.

(51) **Int. Cl.**

A61K 9/14	(2006.01)
A61K 38/39	(2006.01)
A61L 31/12	(2006.01)
A61L 24/10	(2006.01)
A61L 24/06	(2006.01)
A61K 47/42	(2006.01)
A61L 24/00	(2006.01)
A61L 31/04	(2006.01)
A61L 31/14	(2006.01)
A61K 9/70	(2006.01)
A61K 38/36	(2006.01)
A61K 38/48	(2006.01)
A61K 47/34	(2006.01)

(52) **U.S. Cl.**

CPC . ***A61K 47/42*** (2013.01); ***A61K 9/70*** (2013.01); ***A61K 38/363*** (2013.01); ***A61K 38/4833*** (2013.01); ***A61K 47/34*** (2013.01); ***A61L 24/001*** (2013.01); ***A61L 24/0031*** (2013.01); ***A61L 24/06*** (2013.01); ***A61L 31/044*** (2013.01); ***A61L 31/145*** (2013.01); ***A61L 31/146*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,507,244	A	5/1950	Correll
2,558,395	A	6/1951	Studer
3,089,815	A	5/1963	Kupelwieser et al.
4,006,220	A	2/1977	Gottlieb
4,013,078	A	3/1977	Feild
4,124,705	A	11/1978	Rothman et al.
4,164,559	A	8/1979	Miyata et al.
4,179,400	A	12/1979	Tsao et al.
4,265,233	A	5/1981	Sugitachi et al.
4,291,013	A	9/1981	Wahlig et al.
4,292,972	A	10/1981	Pawelchak et al.
4,298,598	A	11/1981	Schwarz et al.
4,300,494	A	11/1981	Graiff et al.
4,347,234	A	8/1982	Wahlig et al.
4,362,567	A	12/1982	Schwarz et al.
4,377,572	A	3/1983	Schwarz et al.
4,424,208	A	1/1984	Wallace et al.
4,453,939	A	6/1984	Zimmerman et al.
4,482,386	A	11/1984	Wittwer et al.
4,515,637	A	5/1985	Cioca
4,536,387	A	8/1985	Sakamoto et al.
4,540,410	A	9/1985	Wood et al.
4,543,332	A	9/1985	Jao et al.
4,554,156	A	11/1985	Fischer et al.
4,600,574	A	7/1986	Lindner et al.
4,640,834	A	2/1987	Eibl et al.
4,655,211	A	4/1987	Sakamoto et al.
4,746,514	A	5/1988	Warne
4,749,689	A	6/1988	Miyata et al.
4,803,075	A	2/1989	Wallace et al.
4,818,517	A	4/1989	Kwee et al.
4,832,686	A	5/1989	Anderson
4,837,285	A	6/1989	Berg et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0132983	A	2/1985
EP	0376931		7/1990

(Continued)

OTHER PUBLICATIONS

Maok (Hemostatic Agents, Adjuncts to Control Bleeding, Today's O.R. Nurse, vol. 13.11 (1991) pp. 6-10; on Oct. 30, 2013 IDS).*

Ansell et al., "Gelfoam and Autologous Clot Embolization: Effect on Coagulation." *Investigative Radiology* vol. 13 (1978): pp. 115-120.

Barrow, D.L., et al.; "The Use of Greater Omentum Vascularized Free Flaps for Neurosurgical Disorders Requiring Reconstruction." *Journal of Neurosurgery*, vol. 60 (Feb. 1984): pp. 305-311.

Barton, et al., "Fibrin Glue as a Biologic Vascular Patch—A Comparative Study." (abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001) *Journal Surgical Research* vol. 40.5 (1986): pp. 510-513.

(Continued)

Primary Examiner — H. Sarah Park

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.

24 Claims, 16 Drawing Sheets